01. Duration starts with the study, not the calendar
“How long can I take it?” combines several questions: how long retatrutide has been studied, how long changes continue, what happens after stopping, and whether a particular person should continue. Those questions need different answers.
RETROD is our name for retatrutide research material. Clinical studies use controlled formulations, defined eligibility criteria and medical follow-up. Their duration is evidence about the studied treatment, not an established safe-use period for a research vial.
The sections below connect each milestone to its source, then address maintenance, interruptions, tolerability, body composition and record keeping.
02. The main research windows
| Study | Duration | Population / focus |
|---|---|---|
| Phase 1b [1] | 12 weeks | Adults with type 2 diabetes; early safety and pharmacokinetics |
| Phase 2 obesity [2] | 48 weeks | 338 adults; body weight |
| Phase 2 diabetes [3] | 36 weeks | 281 adults; glucose and weight |
| MASLD substudy [4] | 48 weeks | 98 participants; MRI-measured liver fat |
| TRANSCEND-T2D-1 [5] | 40 weeks | 537 adults with type 2 diabetes |
| TRIUMPH-4 [6] | 68 weeks | 445 adults; obesity and knee osteoarthritis |
| TRIUMPH-1 [7] | 80 weeks | 2,339 adults with obesity without diabetes |
| TRIUMPH-1 extension [8] | 104 weeks total | 532 selected completers with baseline BMI ≥35 |
Some results are peer-reviewed publications; others are sponsor reports, identified in the sources. A longer observation period helps answer additional questions, but it cannot exclude every rare event or establish indefinite use.
03. Early treatment and escalation in clinical trials
Early-phase research found a half-life of approximately six days. This describes the rate at which exposure declines; it does not specify a safe restart interval after a break. [1]
TRIUMPH-1 used four-week escalation steps. Participants assigned to the 12 mg group progressed through 2, 4, 6 and 9 mg before the target dose; lower-dose groups had shorter escalation paths. Reaching 12 mg therefore involved 16 weeks of escalation. [8]
In the phase 2 obesity trial, gastrointestinal adverse events were dose-related and usually mild to moderate; starting at 2 mg rather than 4 mg partly reduced them. [2]
Trial schedules explain the early timeline. They are not instructions to increase a dose because a date has arrived, nor do they establish that everyone’s appetite or symptoms change in a particular week.
04. What changed between six months and one year?
| Group | Week 24 | Week 48 |
|---|---|---|
| 1 mg | 7.2% | 8.7% |
| 4 mg, combined | 12.9% | 17.1% |
| 8 mg, combined | 17.3% | 22.8% |
| 12 mg | 17.5% | 24.2% |
| Placebo | 1.6% | 2.1% |
The 12 mg group’s difference between these assessments was 6.7 percentage points. At week 48, 100%, 93% and 83% of that group achieved reductions of at least 5%, 10% and 15%, respectively. [2]
These are observations from one trial, not a prediction of a particular monthly rate. A group average does not tell someone when they will reach a chosen target, or whether extending treatment is appropriate.
Keep the denominator clear: percentage body-weight loss uses starting weight, while “percentage points” describes the difference between two percentages.
05. Beyond a year: 68, 80 and 104 weeks
| Outcome | 9 mg | 12 mg | Placebo |
|---|---|---|---|
| Mean weight reduction | 26.4% | 28.7% | 2.1% |
| Achieved ≥25% loss | 47.7% | 58.6% | 1.3% |
| Achieved ≥30% loss | 30.5% | 39.4% | 0.8% |
| Achieved ≥35% loss | 18.2% | 23.7% | 0.0% |
| Achieved ≥70% knee-pain reduction | 73.0% | 67.7% | 26.2% |
The ≥30%, ≥35% and knee-pain responder analyses were not controlled for multiplicity. [6]
The 80-week results
| Group | Treatment-regimen estimand | Efficacy estimand |
|---|---|---|
| 4 mg | 17.6% | 19.0% |
| 9 mg | 23.7% | 25.9% |
| 12 mg | 25.0% | 28.3% |
| Placebo | 3.9% | 2.2% |
The published trial reports treatment-regimen results; the sponsor also reports efficacy-estimand results. [7] [8]
The selected extension
At 104 weeks, the original 12 mg group in the selected extension averaged 30.3% weight reduction under the efficacy estimand. Extension participants had completed the main study and tolerated their assigned treatment, and received a maximum tolerated dose of 9 or 12 mg. [8]
Extension results describe that selected group. They do not show that everyone benefits from two years of treatment, or establish outcomes beyond the observed period.
06. Why the analysis method matters
An efficacy estimand estimates the effect under specified conditions of continuing study treatment. A treatment-regimen estimand includes outcomes regardless of treatment adherence or specified additional treatments. Neither should be presented without its label.
For example, TRIUMPH-4’s 12 mg weight result was 28.7% under the efficacy analysis and 23.7% under the treatment-regimen analysis. [6]
These are two ways to answer a research question, not two different doses. Selecting the larger figure because someone expects perfect adherence does not turn it into their personal forecast.
07. Different outcomes follow different timelines
Liver fat
In the MASLD substudy, the 8 mg and 12 mg groups had relative liver-fat reductions of 81.4% and 82.4% at week 24, and 81.7% and 86.0% at week 48. At week 24, 79% and 86%, respectively, were below 5% liver fat. [4]
These MRI measurements are distinct from body-weight percentages, liver-enzyme tests and fibrosis outcomes.
Blood glucose
The phase 2 diabetes trial reported a 2.02-percentage-point HbA1c reduction in the 12 mg group at week 24 and approximately 16.9% body-weight reduction at week 36. [3]
TRANSCEND-T2D-1 reported HbA1c reductions of 1.7–2.0 percentage points across retatrutide groups at week 40, with up to 16.8% mean weight reduction under its efficacy estimand. [5]
A decision about duration cannot be reduced to a scale reading alone. The relevant outcome depends on the condition being studied and the person’s clinical context.
08. Maintenance and what happens after stopping
Reaching a target and maintaining a result are separate research questions. Evidence from related medicines illustrates why the period after treatment deserves attention, but cannot establish a retatrutide maintenance regimen.
Semaglutide withdrawal
In the STEP 1 extension, 327 participants were followed after treatment and structured lifestyle support ended. The semaglutide group had lost 17.3% by week 68; over the following year it regained 11.6 percentage points, leaving a net 5.6% loss. Several cardiometabolic changes moved back toward baseline. [9]
Tirzepatide withdrawal
SURMOUNT-4 randomized 670 participants after a 36-week lead-in. During the next 52 weeks, those continuing tirzepatide lost another 5.5% on average, while those switched to placebo gained 14.0% relative to their weight at randomization. [10]
These findings do not validate a fixed low-dose RETROD schedule, a particular taper, or dosing every 10–14 days. A post-treatment plan should be agreed with the treating clinician rather than inferred from another compound.
09. Pauses, cycling and restarting
Planned interruptions, missed treatment, surgery and restarting after a prolonged break are different situations. The duration studies above do not supply a universal restart rule for all of them.
Half-life is also different from tolerability. Declining drug exposure does not establish whether someone can comfortably or safely resume their previous amount. Nor does it prove that scheduled “cycles” preserve results or reset a response.
For clinical treatment, the trial team or prescribing clinician should determine what to do after an interruption. Bring the dates, last administered amount, reason for the pause, symptoms and other medications to that discussion. For a laboratory research product, follow its documented research-use conditions.
10. Plateaus: review the pattern before interpreting it
A single unchanged weigh-in does not establish a plateau. Look at comparable measurements over time, alongside waist measurements, symptoms and changes in activity or food intake. Fluid shifts, bowel contents and inconsistent measurement conditions can obscure a trend.
A slowing rate and no change are not the same pattern. Neither automatically means a higher dose is appropriate. A flat scale with a changing waist also cannot, by itself, prove that fat loss and muscle gain are occurring.
A useful review asks: How long has the pattern persisted? Were measurements consistent? Has anything else changed? Is the original goal still clinically appropriate? The answers provide context for a clinician; they do not create an automatic dose-escalation rule.
11. Tolerability over a longer observation period
| Event | 12 mg | Placebo |
|---|---|---|
| Nausea | 43.2% | 10.7% |
| Diarrhoea | 33.1% | 13.4% |
| Constipation | 25.0% | 8.7% |
| Vomiting | 20.9% | 0.0% |
| Altered skin sensation (dysesthesia) | 20.9% | 0.7% |
| Decreased appetite | 18.2% | 9.4% |
| Stopped because of adverse events | 18.2% | 4.0% |
These are participant percentages, not the probability of a symptom at each injection. [6]
In TRANSCEND-T2D-1, adverse-event discontinuation rates were 2.2%, 4.5% and 5.1% for 4, 9 and 12 mg; dysesthesia occurred in 4.4% of the 12 mg group. [5]
Different trials should not be treated as a controlled comparison of tolerability. Symptoms that are persistent, severe or worsening warrant medical assessment rather than an assumption that waiting longer will resolve them.
12. Body composition, nutrition and monitoring
The 36-week DXA substudy enrolled 189 adults with type 2 diabetes. Total fat-mass reduction reached 26.1% in the pooled 8 mg group and 23.2% in the 12 mg group. Lean mass also declined; its share of weight loss was similar to other obesity treatments. [11]
That study did not compare an 8 mg, 68-week regimen against a 12 mg, 30-week regimen. It cannot establish that one such schedule preserves more muscle. Protein intake, resistance activity and functional capacity are useful matters to discuss with a clinician or dietitian, with targets tailored to the individual.
| Record | Useful detail |
|---|---|
| Weight and waist | Date, measurement conditions and trend rather than one reading |
| Symptoms | Onset, severity, duration and relation to treatment changes |
| Nutrition and activity | Appetite, ability to eat and drink, training and strength changes |
| Blood pressure | Readings and any related symptoms, when monitoring is advised |
| Glucose / HbA1c | Clinician-directed testing, especially with diabetes treatment |
| Lipids and liver assessment | Tests selected for the condition; liver enzymes do not measure liver fat directly |
| Medication history | All medicines, supplements and any interruptions |
The testing frequency should follow clinical needs. A generic quarterly or six-month schedule is not a substitute for individual assessment.
13. Comparing study durations across compounds
| Compound | Study duration | Mean body-weight reduction |
|---|---|---|
| Semaglutide 2.4 mg | STEP 1 · 68 weeks | 14.9% versus 2.4% placebo [12] |
| Tirzepatide 5 / 10 / 15 mg | SURMOUNT-1 · 72 weeks | 15.0% / 19.5% / 20.9% versus 3.1% placebo [13] |
| Retatrutide 12 mg | Phase 2 · 48 weeks | 24.2% versus 2.1% placebo [2] |
| Retatrutide 12 mg | TRIUMPH-1 · 80 weeks | 25.0% versus 3.9% placebo; treatment-regimen analysis [7] |
Eligibility, follow-up, escalation and statistical methods differ. These figures cannot tell someone which compound will work fastest for them or what duration is safe.
14. Laboratory supply, storage and records
For research planning, calculate material requirements from an approved laboratory protocol, then account for assay needs, handling losses and usable shelf life. A sample human dosing schedule is not a validated stock-planning template.
Record each vial’s compound, labelled quantity, lot, receipt date and storage instructions. If reconstituted for laboratory work, record the date, diluent and calculated concentration. Use the supplier’s validated stability information for that exact preparation; a six- or twelve-month project does not imply that one prepared vial remains usable for the whole period.
Check COA & Batch Reports for the relevant lot and report status. Our Reconstitution Calculator supports concentration arithmetic, while the reconstitution guide explains the underlying measurements. Neither establishes a clinical regimen or product stability.
15. Frequently asked questions
Is there a fixed maximum number of weeks?
The studies describe defined observation periods. Those endpoints are not a universal safe-use limit or permission to continue indefinitely.
Is twelve weeks enough to judge the final result?
Early assessments and longer-term endpoints answer different questions. Some trial groups were still escalating during the early period. See the dose-group and duration tables above.
Should treatment end at a target weight?
Maintenance needs a separate clinical decision. Withdrawal studies of other medicines show that regain can occur; they do not identify an established RETROD maintenance dose.
Does a plateau mean it stopped working?
A plateau alone does not identify its cause. Review the trend and other relevant changes instead of automatically increasing or restarting treatment.
Can I copy a taper or restart schedule from an online guide?
The cited duration studies do not validate a universal schedule. Clinical decisions about pauses and restarting belong with the treating clinician or trial team.
Do these findings prove benefits for MGMT’s RETROD vials?
No. The findings concern the clinical study products. MGMT’s products are supplied for laboratory research.
16. Sources and related guides
- Urva et al. Phase 1b study of LY3437943 (retatrutide). The Lancet, 2022.
- Jastreboff et al. Retatrutide phase 2 obesity trial. NEJM, 2023.
- Rosenstock et al. Retatrutide phase 2 type 2 diabetes trial. The Lancet, 2023.
- Retatrutide MASLD phase 2a substudy. Nature Medicine, 2024.
- Lilly. TRANSCEND-T2D-1, March 2026. Sponsor report.
- Lilly. TRIUMPH-4, December 2025. Sponsor report.
- Jastreboff et al. TRIUMPH-1. NEJM, September 2026.
- Lilly. TRIUMPH-1 efficacy analysis and 104-week extension, May 2026. Sponsor report.
- Wilding et al. STEP 1 withdrawal extension. Diabetes, Obesity and Metabolism, 2022.
- Aronne et al. SURMOUNT-4 randomized withdrawal trial. JAMA, 2024.
- Coskun et al. Retatrutide body-composition substudy. Lancet Diabetes & Endocrinology, 2025.
- Wilding et al. STEP 1 semaglutide trial. NEJM, 2021.
- Jastreboff et al. SURMOUNT-1 tirzepatide trial. NEJM, 2022.